A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

CHICAGO (Reuters) - Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

Scientists have analyzed thousands of mutations in the BRCA2 cancer gene, offering crucial insights. This research could help mitigate patient concerns or guide tailored treatments. By utilizing ...

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

NICE's endorsement of olaparib, produced by AstraZeneca, marks a crucial step forward in the treatment of breast cancer. This ...

Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas. 2-5 Despite the ...

Mr. Knowles is opening up about something else near and dear to his heart — his experience as a male breast cancer survivor ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...